Literature DB >> 28940102

MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.

Palak Shah1, Michael R Bristow2, J David Port2.   

Abstract

PURPOSE OF REVIEW: Heart failure is increasing in prevalence with a lack of recently developed therapies that produce major beneficial effects on its associated mortality. MicroRNAs are small non-coding RNA molecules that regulate gene expression, are differentially regulated in heart failure, and are found in the circulation serving as a biomarker of heart failure. RECENT
FINDINGS: Data suggests that microRNAs may be used to detect allograft rejection in cardiac transplantation and may predict the degree of myocardial recovery in patients with a left ventricular assist device or treated with beta-blocker therapy. Given their role in regulating cellular function, microRNAs are an intriguing target for oligonucleotide therapeutics, designed to mimic or antagonize (antagomir) their biological effects. We review the current state of microRNAs as biomarkers of heart failure and associated conditions, the mechanisms by which microRNAs control cellular function, and how specific microRNAs may be targeted with novel therapeutics designed to treat heart failure.

Entities:  

Keywords:  Biomarkers; Cardiac transplantation; Heart failure; Mechanical circulatory support; MicroRNAs; Myocardial recovery

Mesh:

Substances:

Year:  2017        PMID: 28940102     DOI: 10.1007/s11897-017-0362-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  97 in total

1.  Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients.

Authors:  Katrina L Ellis; Vicky A Cameron; Richard W Troughton; Chris M Frampton; Leigh J Ellmers; A Mark Richards
Journal:  Eur J Heart Fail       Date:  2013-05-21       Impact factor: 15.534

2.  Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy.

Authors:  Shelley D Miyamoto; Anis Karimpour-Fard; Valencia Peterson; Scott R Auerbach; Kurt R Stenmark; Brian L Stauffer; Carmen C Sucharov
Journal:  J Heart Lung Transplant       Date:  2015-01-30       Impact factor: 10.247

Review 3.  Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review).

Authors:  Alessandro Allegra; Andrea Alonci; Salvatore Campo; Giuseppa Penna; Annamaria Petrungaro; Demetrio Gerace; Caterina Musolino
Journal:  Int J Oncol       Date:  2012-10-01       Impact factor: 5.650

4.  MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.

Authors:  Jayavarshni Ganesan; Deepak Ramanujam; Yassine Sassi; Andrea Ahles; Claudia Jentzsch; Stanislas Werfel; Simon Leierseder; Xavier Loyer; Mauro Giacca; Lorena Zentilin; Thomas Thum; Bernhard Laggerbauer; Stefan Engelhardt
Journal:  Circulation       Date:  2013-04-26       Impact factor: 29.690

5.  Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

Authors:  Rusty L Montgomery; Thomas G Hullinger; Hillary M Semus; Brent A Dickinson; Anita G Seto; Joshua M Lynch; Christianna Stack; Paul A Latimer; Eric N Olson; Eva van Rooij
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

6.  Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*.

Authors:  Michele Carrer; Ning Liu; Chad E Grueter; Andrew H Williams; Madlyn I Frisard; Matthew W Hulver; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

7.  Inhibition of miR-25 improves cardiac contractility in the failing heart.

Authors:  Christine Wahlquist; Dongtak Jeong; Agustin Rojas-Muñoz; Changwon Kho; Ahyoung Lee; Shinichi Mitsuyama; Alain van Mil; Woo Jin Park; Joost P G Sluijter; Pieter A F Doevendans; Roger J Hajjar; Mark Mercola
Journal:  Nature       Date:  2014-03-12       Impact factor: 49.962

8.  Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device.

Authors:  Andrew C Morley-Smith; Adam Mills; Steven Jacobs; Bart Meyns; Filip Rega; André R Simon; John R Pepper; Alexander R Lyon; Thomas Thum
Journal:  Eur J Heart Fail       Date:  2014-06-24       Impact factor: 15.534

9.  RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection.

Authors:  L N L Van Aelst; G Summer; S Li; S K Gupta; W Heggermont; K De Vusser; P Carai; M Naesens; J Van Cleemput; F Van de Werf; J Vanhaecke; T Thum; M Waer; A-P Papageorgiou; B Schroen; S Heymans
Journal:  Am J Transplant       Date:  2015-08-06       Impact factor: 8.086

10.  Improved risk stratification in prevention by use of a panel of selected circulating microRNAs.

Authors:  Till Keller; Jes-Niels Boeckel; Stefan Groß; Jens Klotsche; Lars Palapies; David Leistner; Lars Pieper; Günnter K Stalla; Hendrik Lehnert; Sigmund Silber; David Pittrow; Winfried Maerz; Marcus Dörr; Hans-Ulrich Wittchen; Sebastian E Baumeister; Uwe Völker; Stephan B Felix; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Sci Rep       Date:  2017-07-03       Impact factor: 4.379

View more
  20 in total

Review 1.  Noninvasive biomarkers in heart transplant: 2020-2021 year in review.

Authors:  Xiaoxiao Qian; Palak Shah; Sean Agbor-Enoh
Journal:  Curr Opin Organ Transplant       Date:  2022-02-01       Impact factor: 2.640

2.  Circulating microRNAs in cellular and antibody-mediated heart transplant rejection.

Authors:  Palak Shah; Sean Agbor-Enoh; Pramita Bagchi; Christopher R deFilippi; Angela Mercado; Gouqing Diao; Dave Jp Morales; Keyur B Shah; Samer S Najjar; Erika Feller; Steven Hsu; Maria E Rodrigo; Sabra C Lewsey; Moon Kyoo Jang; Charles Marboe; Gerald J Berry; Kiran K Khush; Hannah A Valantine
Journal:  J Heart Lung Transplant       Date:  2022-06-28       Impact factor: 13.569

3.  Label-free and sensitive MiRNA detection based on turn-on fluorescence of DNA-templated silver nanoclusters coupled with duplex-specific nuclease-assisted signal amplification.

Authors:  Gui-Min Ma; Li-Wei Huo; Yin-Xia Tong; Yu-Cong Wang; Cui-Ping Li; Hong-Xia Jia
Journal:  Mikrochim Acta       Date:  2021-09-28       Impact factor: 5.833

Review 4.  Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.

Authors:  Dinh-Duc Nguyen; Suhwan Chang
Journal:  Int J Mol Sci       Date:  2017-12-27       Impact factor: 5.923

5.  Differential Expression of CircRNAs in Embryonic Heart Tissue Associated with Ventricular Septal Defect.

Authors:  Heng Liu; Yin Hu; Bin Zhuang; Jing Yin; Xiao-Hui Chen; Juan Wang; Meng-Meng Li; Jing Xu; Xing-Yun Wang; Zhang-Bin Yu; Shu-Ping Han
Journal:  Int J Med Sci       Date:  2018-05-14       Impact factor: 3.738

Review 6.  Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Dis Markers       Date:  2020-06-12       Impact factor: 3.434

7.  Application and Evaluation of [99mTc]-Labeled Peptide Nucleic Acid Targeting MicroRNA-155 in Breast Cancer Imaging.

Authors:  Yaqun Jiang; Yongkang Gai; Yu Long; Qingyao Liu; Chunbao Liu; Yongxue Zhang; Xiaoli Lan
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

8.  Sufentanil preconditioning protects against myocardial ischemia/reperfusion injury via miR-125a/DRAM2 axis.

Authors:  Qiaoling Wu; You Shang; Yanli Bai; Yuanyuan Wu; Hao Wang; Tu Shen
Journal:  Cell Cycle       Date:  2021-01-21       Impact factor: 4.534

9.  MiR-133a Mimic Alleviates T1DM-Induced Systolic Dysfunction in Akita: An MRI-Based Study.

Authors:  Shyam Sundar Nandi; Hamid Reza Shahshahan; Quanliang Shang; Shelby Kutty; Michael Boska; Paras Kumar Mishra
Journal:  Front Physiol       Date:  2018-10-10       Impact factor: 4.566

10.  MiR-125b inhibits cardiomyocyte apoptosis by targeting BAK1 in heart failure.

Authors:  Bei Zhang; Shanyong Mao; Xingde Liu; Sha Li; Haiyan Zhou; Ying Gu; Wupeng Liu; Lei Fu; Chunyan Liao; Pengzhen Wang
Journal:  Mol Med       Date:  2021-07-08       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.